107 publications

Name Date Type Actions

[VIDEO ]Présentation des résultats 2020 - french

Présentation analystes & investisseurs - 1er avril 2021

 		01/04/2021 Annual Report

[VIDEO] Présentation des résultats semestriels 2021 - french

Présentation analystes & investisseurs - 29 juillet 2021

 		29/07/2021 Half Year Report

[Video] Présentation des résultats semestriels 2022 - french

Présentation analystes & investisseurs - 15 septembre 2022

 		29/07/2021 Half Year Report

2010 Activity Report

P_06 VÉTOQUINOL’S PROUD HISTORY
<br>
P_12 SPOTLIGHT ON INNOVATION
<br>
P_18 AN ONGOING DAILY COMMITMENT
TO VETERINARIANS
<br>
P_24 AN INTERNATIONAL COMPANY
MAINTAINING A LOCAL PRESENCE
IN GLOBAL MARKETS
<br>
P_28 GOVERNANCE AND KEY FIGURES

 		27/04/2011 Annual Report

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

 		04/04/2011 Public releases

2010 annual earnings Vétoquinol

Contents :
<br>> Highlights
<br>> 2010 Consolidated
Financial Statements
<br>> Strategy and Outlook
<br>> Questions and Answers

 		12/04/2011 Annual Report

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.

 		25/01/2011 Public releases

2011 Half Year Results

2011 Half year results

 		31/08/2011 Half Year Report

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m

 		01/04/2021 Public releases

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”

 		21/01/2021 Public releases